Understanding retatrutide requires understanding each of its three receptor targets individually — because the triple mechanism is not a single stronger version of GLP-1. Each pathway has a distinct biological role, and the combination creates metabolic effects that none of the three could achieve alone. This is not incremental improvement; it is a different class of effect.
GLP-1: The appetite and insulin pathway
GLP-1 (Glucagon-Like Peptide-1) is secreted naturally from intestinal L-cells after meals, acting on the brain to suppress appetite and on the pancreas to stimulate insulin release in proportion to glucose levels. GLP-1 agonism slows gastric emptying, reducing caloric intake both by suppressing hunger and by making smaller amounts of food produce greater satiety signals. This is the mechanism semaglutide uses, and it is the foundation of the entire incretin drug class.
GIP: The nutrient partitioning and amplification pathway
GIP (Glucose-dependent Insulinotropic Polypeptide) is also secreted after meals but acts primarily on fat cells and peripheral tissues rather than the brain. Its roles include enhancing insulin sensitivity in muscle and fat tissue, modulating how the body allocates incoming calories between storage and use, and — critically — amplifying the appetite-suppressing effect of GLP-1 agonism when both receptors are activated together. This amplification is why tirzepatide (GLP-1 + GIP) outperforms semaglutide (GLP-1 alone), and why GIP is an essential component of the retatrutide triple mechanism.
Glucagon: The energy expenditure pathway
The glucagon receptor is the mechanism that makes retatrutide distinct from every GLP-1 class compound that preceded it. Glucagon receptor activation directly stimulates the liver to perform fatty acid oxidation — burning stored fat for energy rather than storing it. It simultaneously suppresses de novo lipogenesis (the synthesis of new fat from dietary carbohydrates), increases basal metabolic rate through thermogenesis, and produces the dramatic liver fat reductions seen in MASLD trial data. Crucially, the elevated blood glucose that would normally result from glucagon activation is controlled by the simultaneous GIP-mediated insulin sensitisation — the three pathways regulate each other.
Why the combination outperforms the sum of its parts
In isolation, combining GLP-1 and glucagon agonism would be problematic: glucagon raises blood glucose while GLP-1 reduces it, creating competing signals. GIP's insulin-sensitising role resolves this competition, allowing the glucagon metabolic benefit (increased fat burning and energy expenditure) without the glucose liability. The result is a compound that simultaneously reduces food intake, increases fat oxidation, and raises resting energy expenditure — three independent weight loss mechanisms operating concurrently, each amplifying the effectiveness of the others.